**REVIEW**

7272  Challenges in COVID-19 drug treatment in patients with advanced liver diseases: A hepatology perspective

*Hanafy AS, Abd-Elalam S*

---

**MINIREVIEWS**

7287  Evolving role of artificial intelligence in gastrointestinal endoscopy

*Parasher G, Wong M, Rawat M*

---

**ORIGINAL ARTICLE**

**Basic Study**

7299  Untargeted metabolomics characteristics of nonobese nonalcoholic fatty liver disease induced by high-temperature-processed feed in Sprague-Dawley rats

*Xue LJ, Han JQ, Zhou YC, Peng HY, Yin TF, Li KM, Yao SK*

7312  Extrahepatic bile duct reconstruction in pigs with heterogenous animal-derived artificial bile ducts: A preliminary experience


---

**Case Control Study**

7325  Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma


7338  Response of gut microbiota to serum metabolome changes in intrahepatic cholestasis of pregnant patients

*Li GH, Huang SJ, Li X, Liu XS, Du QL*

7352  Colonic vitamin D receptor expression is inversely associated with disease activity and jumonji domain-containing 3 in active ulcerative colitis

*Wang HQ, Zhang WH, Wang YQ, Geng XP, Wang MW, Fan YY, Guan J, Shen JL, Chen X*

---

**Retrospective Study**

7367  Prevalence and risk factors of nonalcoholic fatty liver disease in patients with inflammatory bowel diseases: A cross-sectional and longitudinal analysis

*Hoffmann P, Jung V, Behnisch R, Gauss A*

7382  Prognostic value of the preoperative fibrinogen-to-albumin ratio in pancreatic ductal adenocarcinoma patients undergoing R0 resection

*Zhang LP, Ren H, Du YX, Wang CF*
### Clinical Trials Study

7405  Effect of postoperative early enteral nutrition on clinical outcomes and immune function of cholangiocarcinoma patients with malignant obstructive jaundice

*Ma BQ, Chen SY, Jiang ZB, Wu B, He Y, Wang XX, Li Y, Gao P, Yang XJ*

### Prospective Study

7416  Value of shear wave elastography with maximal elasticity in differentiating benign and malignant solid focal liver lesions

*Zhang HP, Gu JY, Bai M, Li F, Zhou YQ, Du LF*

### CASE REPORT

7425  Infliximab is effective in the treatment of ulcerative colitis with dermatomyositis: A case report

*Huang BB, Han LC, Liu XD, Gu GL, Li SQ, Chen L, Wang HQ, Zhan LL, Lv XP*
ABOUT COVER

Editorial Board Member of World Journal of Gastroenterology, Dr. Oscar Tatsuya Teramoto-Matsubara received his bachelor’s degree from Universidad La Salle (Mexico City, Mexico) in 1986, after which he completed a residency in gastroenterology at the Centro Médico Nacional del Instituto Mexicano del Seguro Social. From 2016 to 2018, he served as President of the Asociación Latinoamericana de Neurogastroenterología; he also served as an editorial board member of the Association’s official journal, Neurogastro Latam Journal. His current clinical research interests involve gastroesophageal reflux disease and other topics related to functional bowel disorders. In endoscopy practice, he is involved in quality assurance of upper and lower endoscopy procedures. Currently, Dr. Teramoto-Matsubara is Assistant Professor at Universidad La Salle and Universidad Anáhuac. (L-Editor: Filipodia)

AIMS AND SCOPE

The primary aim of World Journal of Gastroenterology (WJG, World J Gastroenterol) is to provide scholars and readers from various fields of gastroenterology and hepatology with a platform to publish high-quality basic and clinical research articles and communicate their research findings online. WJG mainly publishes articles reporting research results and findings obtained in the field of gastroenterology and hepatology and covering a wide range of topics including gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery, gastrointestinal oncology, and pediatric gastroenterology.

INDEXING/ABSTRACTING

The WJG is now indexed in Current Contents®/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch®), Journal Citation Reports®, Index Medicus, MEDLINE, PubMed, PubMed Central, and Scopus. The 2020 edition of Journal Citation Report® cites the 2019 impact factor (IF) for WJG as 3.665; IF without journal self cites: 3.534; 5-year IF: 4.048; Ranking: 35 among 88 journals in gastroenterology and hepatology; and Quartile category: Q2.

RESPONSIBLE EDITORS FOR THIS ISSUE

Production Editor: Ji-Hong Liu; Production Department Director: Yun-Xiaoqian Wu; Editorial Office Director: Ze-Mao Gong.

NAME OF JOURNAL

World Journal of Gastroenterology

ISSN

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

LAUNCH DATE

October 1, 1995

FREQUENCY

Weekly

EDITORS-IN-CHIEF

Andrzej S Tarnawski, Subrata Ghosh

EDITORIAL BOARD MEMBERS

http://www.wjgnet.com/1007-9327/editorialboard.htm

PUBLICATION DATE

December 14, 2020

COPYRIGHT

© 2020 Baishideng Publishing Group Inc

INSTRUCTIONS TO AUTHORS

https://www.wjgnet.com/bpg/gerinfo/204

GUIDELINES FOR ETHICS DOCUMENTS

https://www.wjgnet.com/bpg/GerInfo/287

GUIDELINES FOR NON-NATIVE SPEAKERS OF ENGLISH

https://www.wjgnet.com/bpg/gerinfo/240

PUBLICATION ETHICS

https://www.wjgnet.com/bpg/GerInfo/288

PUBLICATION MISCONDUCT

https://www.wjgnet.com/bpg/gerinfo/242

ARTICLE PROCESSING CHARGE

https://www.wjgnet.com/bpg/gerinfo/239

STEPS FOR SUBMITTING MANUSCRIPTS

https://www.wjgnet.com/bpg/gerinfo/239

ONLINE SUBMISSION

https://www.f6publishing.com

© 2020 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

E-mail: bpgoffice@wjgnet.com https://www.wjgnet.com
Clinical Trials Study

Effect of postoperative early enteral nutrition on clinical outcomes and immune function of cholangiocarcinoma patients with malignant obstructive jaundice

Bing-Qiang Ma, Shi-Yong Chen, Ze-Bin Jiang, Biao Wu, Yu He, Xin-Xin Wang, Yuan Li, Peng Gao, Xiao-Jun Yang

ORCID number: Bing-Qiang Ma 0000-0002-0254-6547; Shi-Yong Chen 0000-0003-2678-7019; Ze-Bin Jiang 0000-0002-6499-8311; Biao Wu 0000-0003-4792-1133; Yu He 0000-0002-7127-3773; Xin-Xin Wang 0000-0003-4622-677X; Yuan Li 0000-0002-4994-9773; Peng Gao 0000-0001-7016-6485; Xiao-Jun Yang 0000-0003-3770-8451.

Author contributions: Ma BQ, Chen SY, and Jiang ZB contributed equally to this work and should be considered as co-first authors; Ma BQ, Chen SY, Jiang ZB, and Yang XJ conceived the experiment; Ma BQ and Jiang ZB analyzed the results; Ma BQ and Chen SY wrote the original draft; Ma BQ, Chen SY, Jiang ZB, Wu B, He Y, Wang XX, Li Y, Gao P, and Yang XJ conducted the experiment; All the authors revised the manuscript and approved the final version.

Supported by National Natural Science Foundation of China, No. 81660398; and The Hospital Key Program of National Scientific Research Cultivation Plan, No. 19SYPYA-12.

Institutional review board statement: The study was approved by the institutional review board of Gansu Provincial Hospital.

Abstract

BACKGROUND
Most cholangiocarcinoma patients with malignant obstructive jaundice (MOJ) have varying degrees of malnutrition and immunodeficiency preoperatively. Therefore, perioperative nutritional support has important clinical significance in the treatment of cholangiocarcinoma.

AIM
To investigate the effects of postoperative early enteral nutrition (EEN) on immunity function and clinical outcomes of cholangiocarcinoma patients with MOJ.

METHODS
This prospective clinical study included 60 cholangiocarcinoma patients with MOJ who underwent surgery. The patients were randomly divided into an experimental group and a control group according to the nutrition support modes. The control group received postoperative total parenteral nutrition (TPN), whereas the experimental group received postoperative EEN and parenteral nutrition (PN; EEN + PN). The clinical outcomes, postoperative immune function, incidences of surgical site infection and bile leakage, intestinal function recovery time, average hospitalization days, and hospitalization expenses of the two groups were assessed on postoperative days (PODs) 1, 3, and 7.

Citation: Ma BQ, Chen SY, Jiang ZB, Wu B, He Y, Wang XX, Li Y, Gao P, Yang XJ. Effect of postoperative early enteral nutrition on clinical outcomes and immune function of cholangiocarcinoma patients with malignant obstructive jaundice. World J Gastroenterol 2020; 26(46): 7405-7415

DOI: https://dx.doi.org/10.3748/wjg.v26.i46.7405

INTRODUCTION
Cholangiocarcinoma with malignant obstructive jaundice (MOJ) is a malignant tumor originating from the bile duct epithelium. According to their locations, cholangiocarcinomas are divided into intrahepatic and extrahepatic groups (ECC). This study refers to ECC. Radical surgical resection is the most commonly used method for the treatment of cholangiocarcinoma and is still the only method that can achieve long-term survival of patients.

However, impaired lipid digestion and absorption in patients with cholangiocarcinoma may result from decreased bile flow into the intestine due to bile duct obstruction and inflammation[1]. Most cholangiocarcinoma patients with MOJ have varying degrees of malnutrition and immunodeficiency preoperatively[2-5]; therefore, perioperative nutritional support has important clinical significance in the comprehensive treatment of cholangiocarcinoma.

In this study, the clinical data of 56 cholangiocarcinoma patients with MOJ who...
underwent surgery were collected. The clinical value of early enteral nutrition (EEN) support in these patients was evaluated using a statistical analysis of the effects of different nutritional support methods on postoperative immune function.

MATERIALS AND METHODS

Study design
This was a prospective, single-center, randomized clinical trial. The patients were randomly assigned to either the EEN and parenteral nutrition (EEN + PN) or total parenteral nutrition (TPN) group after surgery. We used simple or complete randomization, which is a grouping method based on the remaining random numbers. After a random number was generated, the remaining grouping method (divided by two) was performed in a computer to determine which group the patient was assigned to, either the EEN + PN or TPN group. The treatment allocation was concealed from the patients included in the study and was not deleted from the study after it was made known to the patients. The main difference between the two groups was the nutritional support mode, so blinding the treating physicians to the treatment allocation was not possible. As the included patients had no knowledge of the treatment allocation, this study was considered a single-blind clinical trial. This study was approved by the ethics committee of Gansu Provincial Hospital (approval No. 2016-036), and all the programs were performed after the patients or their relatives signed the informed consent form. This study was registered at the Chinese Clinical Trial Registry, under registration identification No. ChiCTR2000034561. Figure 1 shows the flowchart of the participants.

Patients
All adult patients (aged 18-70 years) who were admitted to the Department of General Surgery of Gansu Provincial Hospital between November 2016 and June 2019 under the diagnosis of ECC were included in this prospective clinical study.

The inclusion criteria were as follows: (1) Patients whose total bilirubin level exceeded 17.1 µmol/L and who could understand the purpose of the study and signed the informed consent form; (2) Patients with preoperative nutrition risk screening (NRS) score ≥ 3 points (the European Society for Parenteral Nutrition 2002 recommendation standard); (3) Patients with a histological diagnosis of ECC with obstructive jaundice indicated for choledochojenu stomy or pancreatoduodenectomy; (4) Patients with Child-Pugh liver function class A or B; (5) Patients who underwent all operations by the same team of surgeons; and (6) Patients whose bilirubin levels were reduced to 50-125 µmol/L before operation.

The exclusion criteria were as follows: (1) Patients who could not cooperate to complete the relevant investigation or examination; (2) Patients who accepted palliative operation; (3) Patients with cardiovascular, liver, kidney, brain, lung, or other serious diseases or those with poor control of hypertension or diabetes; (4) Pregnant or lactating patients; (5) Extremely weak patients with malignant fluids in the late stage of cancer; (6) Patients with mental illness; (7) Patients who participated in other clinical trials within 1 mo prior to participation in this study; and (8) Patients who were unsuitable to participate in this clinical study on the basis of the evaluation performed by the researchers.

Preoperative assessment
Preoperative parenteral nutrition was given according to the patient's nutritional status. Patients with preoperative total bilirubin greater than 200 µmol/L were treated with preoperative biliary drainage therapy, such as percutaneous transhepatic cholangial drainage or endoscopic nasobiliary drainage. The bilirubin of patients with cholangiocarcinoma dropped to around 200 µmol/L, and patients with Child-Pugh liver function was class A or B, so surgical treatment can be considered.

Nutritional support mode
The postoperative nutritional support was based on a 40-mL/(kg day) liquid volume and total energy levels of 10, 20, 30, and 35 kcal/kg on the first, second, third, and following days, respectively (Table 1). In the EEN + PN group, a 10-F nasojejunal feeding tube (Flocare, Nutricia Ltd, Paris, France) was placed as needed. EN (Peptisorb, Nutricia Ltd) was used on postoperative day (POD) 2, and PN was used as a supplement in the case of insufficient EN. In the TPN group, a 10-F nasojejunal
Ma BQ et al. EEN and cholangiocarcinoma patients with MOJ

Table 1 Nutrition supply postoperatively

<table>
<thead>
<tr>
<th>Group</th>
<th>Nutritional support</th>
<th>POD 1</th>
<th>POD 2</th>
<th>POD 3</th>
<th>POD 4</th>
<th>POD 5</th>
<th>POD 6</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPN group</td>
<td>PN</td>
<td>10 kcal/kg</td>
<td>20 kcal/kg</td>
<td>30 kcal/kg</td>
<td>35 kcal/kg</td>
<td>35 kcal/kg</td>
<td>35 kcal/kg</td>
</tr>
<tr>
<td></td>
<td>EN</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>EEN + PN group</td>
<td>PN</td>
<td>10 kcal/kg</td>
<td>10 kcal/kg</td>
<td>10 kcal/kg</td>
<td>5 kcal/kg</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>EN</td>
<td>0</td>
<td>10 kcal/kg</td>
<td>20 kcal/kg</td>
<td>30 kcal/kg</td>
<td>35 kcal/kg</td>
<td>35 kcal/kg</td>
</tr>
</tbody>
</table>

EEN: Early enteral nutrition; EN: Enteral nutrition; PN: Parenteral nutrition; POD: Postoperative day; TPN: Total parenteral nutrition.

Data collection

On admission, the baseline data, including sex, age, NRS score, total bilirubin level, and jaundice duration, were collected. The general postoperative indicators, namely bile leakage, surgical site infection, abdominal distention, intestinal function recovery time, length of postoperative hospital stay, and total cost of hospitalization, in all the patients were recorded and compared. Multiple indicators of immune function and nutritional status were evaluated in all the patients before surgery and on PODs 1, 3, and 7. Immune function was assessed by measuring the counts of the blood lymphocyte subsets (CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cells) and serum immunoglobulin (Ig) G, IgM, and IgA levels (g/L). T-cell subpopulations (CD3+T, CD4+T, and CD8+T) and serum IgG, IgM, and IgA were detected with commercially available human Quantikine enzyme-linked immunosorbent assay kits (R and D Systems, Bio-Techne Corporation, Minneapolis, MN, United States) in accordance with the manufacturer’s instructions.
Statistical analysis
GraphPad Prism 8 (San Diego, CA, United States) and SPSS 22.0 package (SPSS Inc., Armonk, NY, United States) was used to perform the analysis. Continuous variables were expressed as the mean ± standard deviation. An independent samples t-test was used to compare differences between the two groups. Categorical variables were expressed as absolute and relative frequencies. The Chi-square test or Fisher’s exact test were used to compare the differences in proportions between the two groups. A two-sided P value < 0.05 was considered statistically significant.

RESULTS

Baseline data of the study population
As shown in Figure 1, 60 patients were enrolled in this randomized clinical trial during the study period. Of these patients, 28 received EEN + PN, and 30 received TPN. There were two patients in the EEN + PN group who dropped out for adverse reactions of early enteral feeding, and 56 patients were analyzed in this study in the end. The comparison of the basic data before surgery and on POD 1 between the two groups revealed no significant differences between the two groups in terms of sex, age, preoperative NRS score, serum total bilirubin level, disease duration of jaundice, or the proportion of patients who underwent percutaneous transhepatic cholangial drainage (all P > 0.05), which were comparable (Table 2). We found no significant differences in operation methods, operation time, intraoperative blood loss, and NRS score on POD 1 between the two groups (all P > 0.05), as shown in Table 3.

Changes in the related cellular and humoral immune indexes in the two groups
In the EEN + PN group, compared with the preoperative counts, the CD3+T, CD4+T, and CD4+T/CD8+T cell counts were all decreased on POD 1 (P < 0.05; Figure 2) and then began to increase on POD 3 and were all higher on POD 7 (P < 0.05), but the change in CD8+T cell count was not significant (P > 0.05; Figure 2C). In the TPN group, the CD3+T, CD4+T, and CD4+T/CD8+T cell counts decreased on POD 1 (P < 0.05). The CD3+T and CD8+T cell counts continued to decrease on POD 3 and began to increase on POD 7 but were both lower than the preoperative counts (P < 0.05; Figure 2A). The CD4+T and CD4+T/CD8+T cell counts increased from PODs 3 to 7 but were still lower than the preoperative counts (P < 0.05; Figure 2B and Figure D). No significant differences in the CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cell counts before surgery and on POD 1 were found between the two groups (P > 0.05). The CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cell counts in the EEN + PN group were significantly higher than those in the TPN group on PODs 3 and 7 (P < 0.05).

In the EEN + PN group, the IgG, IgA, and IgM levels decreased on POD 1 as compared with the preoperative levels (P < 0.05) and gradually increased on POD 3 and were significantly higher on POD 7 as compared with the preoperative levels (P < 0.05; Figure 3). In the TPN group, as compared with the preoperative levels, the IgG, IgA, and IgM levels began to decrease on POD 1 (P < 0.05) and slightly increased on POD 7 but were still lower than those before operation (P < 0.05).

Postoperative complications of the ECC patients with MOJ
The incidence of abdominal distention in the EEN + PN group was significantly higher than that in the TPN group (P < 0.05), which mostly occurred on PODs 1 to 3. In the TPN group, two patients had abdominal distention until POD 9. No significant differences in the incidence rates of bile leakage and infections at the surgical site were found between the two groups (P > 0.05), as shown in Table 4.

Comparison of recovery time of intestinal function, hospitalization time, and total cost of hospitalization
The recovery time of intestinal function in the EEN + PN group was significantly shorter than that in the TPN group (P < 0.001). The hospitalization time and total cost in the EEN + PN group were shorter or lower than those in the TPN group (P < 0.01), as shown in Table 5.
Table 2 Baseline data before operation

<table>
<thead>
<tr>
<th>Group</th>
<th>Number of cases</th>
<th>Age in yr, mean ± SD</th>
<th>Gender of cases, M/F</th>
<th>NRS score, mean ± SD</th>
<th>Total bilirubin as µmol/L, mean ± SD</th>
<th>Jaundice duration in d, mean ± SD</th>
<th>PTCD cases</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPN group</td>
<td>30</td>
<td>58.90 ± 7.42</td>
<td>18/12</td>
<td>4.03 ± 0.78</td>
<td>100.26 ± 19.18</td>
<td>21.26 ± 9.16</td>
<td>16</td>
</tr>
<tr>
<td>EEN + PN group</td>
<td>26</td>
<td>59.08 ± 7.64</td>
<td>15/11</td>
<td>4.08 ± 0.78</td>
<td>96.50 ± 18.01</td>
<td>18.96 ± 8.89</td>
<td>18</td>
</tr>
<tr>
<td>t or χ²</td>
<td></td>
<td></td>
<td></td>
<td>0.089</td>
<td>0.031</td>
<td>0.239</td>
<td></td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td></td>
<td></td>
<td>0.929¹</td>
<td>0.861²</td>
<td>0.812¹</td>
<td>0.455¹</td>
</tr>
</tbody>
</table>

¹t-test.
²Chi-square test. EEN: Early enteral nutrition; F: Female; M: Male; NRS: Nutrition risk screening; PN: Parenteral nutrition; PTCD: Percutaneous transhepatic cholangial drainage; SD: Standard deviation; TPN: Total parenteral nutrition.

Table 3 Comparison of operation methods and relevant data

<table>
<thead>
<tr>
<th>Basic data</th>
<th>EEN + PN group, n = 26</th>
<th>TPN group, n = 30</th>
<th>t or χ²</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Operation methods by case</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pancreatoduodenectomy</td>
<td>12</td>
<td>20</td>
<td>2.393</td>
<td>0.122¹</td>
</tr>
<tr>
<td>Choledochojejunostomy</td>
<td>14</td>
<td>10</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Operative duration in h, mean ± SD</td>
<td>3.27 ± 0.88</td>
<td>2.84 ± 0.90</td>
<td>1.802</td>
<td>0.077²</td>
</tr>
<tr>
<td>Amount of bleeding in mL, mean ± SD</td>
<td>476.00 ± 187.71</td>
<td>524.00 ± 169.61</td>
<td>1.005</td>
<td>0.319²</td>
</tr>
<tr>
<td>NRS score on the first day after operation by score, mean ± SD</td>
<td>4.25 ± 0.74</td>
<td>4.21 ± 0.88</td>
<td>0.183</td>
<td>0.856¹</td>
</tr>
</tbody>
</table>

¹t-test.
²Chi-square test. EEN: Early enteral nutrition; NRS: Nutrition risk screening; PN: Parenteral nutrition; SD: Standard deviation; TPN: Total parenteral nutrition.

Table 4 The incidence of abdominal distention, bile leakage, and infection of operation site in the two groups, n (%)

<table>
<thead>
<tr>
<th></th>
<th>Cases</th>
<th>Abdominal distention</th>
<th>Bile leakage</th>
<th>Surgical site infection</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPN group</td>
<td>30</td>
<td>4 (13.33)</td>
<td>4 (13.33)</td>
<td>5 (16.67)</td>
</tr>
<tr>
<td>EEN + PN group</td>
<td>26</td>
<td>11 (42.31)</td>
<td>2 (7.96)</td>
<td>2 (7.96)</td>
</tr>
<tr>
<td>Total</td>
<td>56</td>
<td>15 (26.79)</td>
<td>6 (10.71)</td>
<td>7 (12.50)</td>
</tr>
<tr>
<td>P value</td>
<td></td>
<td>0.018</td>
<td>0.675</td>
<td>0.431</td>
</tr>
</tbody>
</table>

Fisher’s exact test. EEN: Early enteral nutrition; PN: Parenteral nutrition; TPN: Total parenteral nutrition.

DISCUSSION

Many studies have found that EN can improve the metabolism of patients, promote the early recovery of liver and gastrointestinal functions, and significantly reduce the incidence of infection in perioperative patients⁵,⁶. At the same time, in a study with patients in the intensive care unit⁷, EN was found to show a stronger immune improvement effect on patients and lower concurrent infection rate. These results suggest that EN support may have a regulatory effect on the immune function of the body. Immune surveillance of tumors is mainly dependent on cellular immunity. As one of the main effector cells, T lymphocytes play an important role in tumor immunity. They are divided into CD4⁺T and CD8⁺T cells, and a decreased ratio of CD4⁺T/CD8⁺T cells represents a decrease in immunity⁸. CD4⁺T cells, as helper T lymphocytes, play an important role in tumor immune surveillance. Humoral immunity is mediated by antibodies in vivo or substances with antibody activity. IgG, IgM, and IgA are non-specific antibodies, which are the main substances of mediated liquid immunity⁹, and humoral immunity mainly prevents infection. After surgery,
Table 5 Comparison of recovery time of intestinal function, hospitalization time, and total cost of hospitalization, mean ± standard deviation

<table>
<thead>
<tr>
<th>Cases</th>
<th>Recovery time of intestinal function after operation in h</th>
<th>Postoperative hospital stay in d</th>
<th>Cost of hospitalization in RMB</th>
</tr>
</thead>
<tbody>
<tr>
<td>TPN group</td>
<td>30</td>
<td>72.0 ± 12.9</td>
<td>9.7 ± 1.5</td>
</tr>
<tr>
<td>EEN + PN group</td>
<td>26</td>
<td>51.2 ± 4.4</td>
<td>8.7 ± 0.8</td>
</tr>
<tr>
<td>t</td>
<td>7.828</td>
<td>3.043</td>
<td>9.285</td>
</tr>
<tr>
<td>P value</td>
<td>&lt; 0.001</td>
<td>0.004</td>
<td>&lt; 0.001</td>
</tr>
</tbody>
</table>

*t-test. EEN: Early enteral nutrition; PN: Parenteral nutrition; TPN: Total parenteral nutrition.

**Figure 2 Difference in the counts of CD3+T, CD4+T, CD8+T, and the CD4+T/CD8+T cell ratios between the early enteral nutrition + parenteral nutrition and total parenteral nutrition groups.**

A: Difference in the counts of CD3+T between the early enteral nutrition + parenteral nutrition (EEN + PN) and total parenteral nutrition (TPN) groups; B: Difference in the counts of CD4+T between the EEN + PN and TPN groups; C: Difference in the counts of CD8+T between the EEN + PN and TPN groups; D: Differences in the CD4+T/CD8+T cell ratios between the EEN + PN and TPN groups. *P < 0.05. EEN: Early enteral nutrition; PN: Parenteral nutrition; POD: Postoperative day; TPN: Total parenteral nutrition.

EN can effectively stimulate the immune system, rapidly increase the ratios of CD3+T, CD4+T, CD8+T cells, and CD4+T/CD8+T cells in peripheral blood[10], and increase the plasma immunoglobulin level[11].

At present, many studies have been conducted on postoperative nutritional support in patients with digestive system tumors such as gastric, colorectal, and esophageal cancers. Owing to the specific location of cholangiocarcinoma, the early diagnosis rate is low, the root treatment surgery is traumatic, the complication rates are high, and patients are often accompanied by malnutrition risk or malnutrition[12], which is not only a complication of cancer but also a disease condition related to one of the reasons for general health deterioration[13]. In recent years, with the development of nutritional support, more in-depth research on nutritional support has been conducted. TPN has
Figure 3 Difference in the serum immunoglobulin G, immunoglobulin M, and immunoglobulin A levels between the early enteral nutrition + parenteral nutrition and total parenteral nutrition groups. A: Difference in the serum immunoglobulin (Ig) G levels between the early enteral nutrition + parenteral nutrition (EEN + PN) and total parenteral nutrition (TPN) groups; B: Difference in the serum IgM levels between the EEN + PN and TPN groups; C: Difference in the serum IgA levels between the EEN + PN and TPN groups. *P < 0.05. EEN: Early enteral nutrition; PN: Parenteral nutrition; POD: Postoperative day; TPN: Total parenteral nutrition.

been found to cause possibly liver function damage such as intrahepatic cholestasis\(^1\) and increase the risk of infection in patients, while EN has no such complications\(^2\). In a study in patients with esophageal cancer\(^3\), immune-enhanced EN not only corrected malnutrition but also regulated the immune function impairment and enhanced the anti-tumor effect of T lymphocytes.

The human immune system mainly includes cellular and humoral immunities. However, patients with cholangiocarcinoma have more trauma during operation, and most of them have obstructive jaundice and incomplete liver function preoperatively. In addition, their food intake before operation is insufficient, which may lead to low immune function, intestinal mucosa barrier damage, and increased postoperative complication and mortality rates\(^4\). When patients with cholangiocarcinoma developed obstructive jaundice, the total number of lymphocytes decreased, the risk of infection increased\(^5\), the immune function of the intestinal mucosa was damaged so that bacteria and endotoxins in the blood could not be effectively removed\(^6\), and sepsis was ultimately more likely to occur. The enteral nutrient solution is absorbed in the intestine, enters the liver through the portal vein, and finally transforms into the liver, which not only supplies nutrition to the body but also provides comprehensive demand for the gastrointestinal mucosa. In addition, it activates the intestinal neuroendocrine system, promotes the growth of the gastrointestinal mucosa, maintains the normal immune functions of the intestine and body, maintains the integrity of the intestinal mucosa function, and blocks the heterotopia of the flora\(^7\). EEN can promote the recovery of intestinal function, reduce the degree of abdominal distention, and shorten the time of abdominal distention\(^8\). Moreover, studies have shown that EN is more reasonable within 24 h after operation\(^9\). In a study on postoperative abdominal surgery, PN with postoperative EEN not only improved the nutritional status of patients with tumors but also
reduced the incidence of postoperative complications\cite{24,25}. The gastrointestinal tract function is not complete after the operation for obstructive jaundice and the absorption capacity of nutrition is reduced\cite{26}. EN not only has a protective effect on the immune function of the intestinal mucosa\cite{27} but also is conducive to the recovery of liver function\cite{28}, which can improve the postoperative nutrition of patients, promote the recovery of intestinal function, and reduce the incidence of bile leakage\cite{29}.

In this study, we found that the immunological indexes began to recover on the third day after radical operation of cholangiocarcinoma, and the CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cell counts and IgG, IgM, and IgA levels in the patients with EEN support were significantly higher than those in the patients with TPN support. Combined with the literature analysis, our findings showed that the causes of this phenomenon are not only related to postoperative cholangiocarcinoma, which affects the participation of bile in enterohepatic circulation and the balance of nutrient absorption after the release of obstruction\cite{30}, but also more closely related to the maintenance of the intestinal mucosal barrier and improvement of immune function\cite{31,32}. The use of postoperative EN had significant advantages over TPN in terms of recovery time of intestinal function and total hospitalization cost ($P < 0.05$), but the incidence of abdominal distention in the EEN + PN group (42.31%) was higher than that in the TPN group (13.33%; $P < 0.05$). However, abdominal distention also occurred in the TPN group, and the duration of abdominal distention in the EEN + PN group was longer than that in the TPN group. We found no significant differences in the incidence rates of infections in the surgical site and bile leakage and length of stay after surgery ($P > 0.05$).

**CONCLUSION**

In conclusion, from the results of this study, as compared with TPN support alone, early use of EN support in ECC patients with MOJ not only can promote the recovery of immune function but also can significantly promote the recovery of gastrointestinal function, reduce the total treatment cost, and be used safely. However, long-term follow-up is needed, and statistical data from a large number of cases is needed to determine whether EN support has an impact on the survival time of patients with cholangiocarcinoma after surgery. Its role in immune monitoring for tumors needs further study.

**ARTICLE HIGHLIGHTS**

**Research background**
Most cholangiocarcinoma patients with malignant obstructive jaundice (MOJ) have varying degrees of malnutrition and immunodeficiency preoperatively.

**Research motivation**
Perioperative nutritional support has important clinical significance in the comprehensive treatment of cholangiocarcinoma.

**Research objectives**
We aimed to investigate the effects of postoperative early enteral nutrition (EEN) on immunity function and clinical outcomes of cholangiocarcinoma patients with MOJ.

**Research methods**
The patients were randomly divided into an experimental group and a control group according to the nutrition support modes. The control group received postoperative total parenteral nutrition (TPN), whereas the experimental group received postoperative EEN and parenteral nutrition (PN; EEN + PN). The clinical outcomes, postoperative immune function, incidences of surgical site infection and bile leakage, intestinal function recovery time, average hospitalization days, and hospitalization expenses of the two groups were assessed on postoperative days (PODs) 1, 3, and 7.

**Research results**
The CD3+T, CD4+T, CD8+T, and CD4+T/CD8+T cell counts and the immunoglobulin (Ig) G, IgM, and IgA levels in the EEN + PN group were significantly higher than
those in the TPN group on PODs 3 and 7 ($P < 0.05$), whereas no significant differences in the CD3+, CD4+, CD8+, and CD4+/CD8+ cell counts and IgG, IgM, and IgA levels before operation and on POD 1 were found between the two groups ($P > 0.05$). The intestinal function recovery time and postoperative hospital stay were shorter ($P < 0.001$ for both) in the EEN + PN group than in the TPN group. The hospitalization expenses of the EEN + PN group were lower than those of the TPN group ($P < 0.001$). However, the incidence of abdominal distension was higher than in the EEN + PN group than in the TPN group ($P < 0.05$). The incidence rates of biliary leakage and surgical site infection were not significantly different between the two groups ($P > 0.05$).

**Research conclusions**

A postoperative EEN program could reduce the incidence of postoperative complications and improve the clinical outcomes and immune functions of cholangiocarcinoma patients with MOJ and is thus beneficial to patient recovery.

**Research perspectives**

Long-term follow-up is needed, and statistical data from a large number of cases are needed to determine whether EN support has an impact on the survival time of patients with cholangiocarcinoma after surgery.

**REFERENCES**


Ma BQ et al. EEN and cholangiocarcinoma patients with MOJ

DOI: 10.1590/s0104-42302009000400011


Wan SL, Li YC. Early administration of enteral nutrition after surgical resection of hilar cholangiocarcinoma. Zhongguo Putong Waike Za Zhi 2012


